PG
EGRX

PEAK6 Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

PEAK6 Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$1.47M Hold
19,400
– – 0.01% 1634
2018
Q1 		$1.02M Buy
+19,400
New +$1.13M ﹤0.01% 1949
2016
Q3 		– Sell
-10,000
Closed -$388K – 4811
2016
Q2 		$388K Hold
10,000
– – ﹤0.01% 2590
2016
Q1 		$405K Buy
+10,000
New +$634K ﹤0.01% 2473
2015
Q3 		– Sell
-6,000
Closed -$485K – 5691
2015
Q2 		$485K Buy
+6,000
New +$391K ﹤0.01% 2792

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

PEAK6 Group's EGRX Position: Q2 2018 in Review

PEAK6 Group reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 82% in Q2 2018, selling an estimated $332K and leaving 1,163 shares worth $88K. The position accounts for ﹤0.01% of the portfolio, ranked #3750.

PEAK6 Group first reported a position in EGRX in Q2 2015 and has held it in 5 quarters since. The position peaked at $349K in Q2 2016. 183 funds tracked by Wall St. Rank hold EGRX as of Q2 2018.

  • PEAK6 Group held 1,163 shares of Eagle Pharmaceuticals, Inc. worth $88K as of Q2 2018.
  • PEAK6 Group sold 5,281 Eagle Pharmaceuticals, Inc. shares in Q2 2018, an estimated $332K.
  • Eagle Pharmaceuticals, Inc. made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #3750 holding.
  • PEAK6 Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and has held it in 5 quarters since.
  • PEAK6 Group's Eagle Pharmaceuticals, Inc. position peaked at $349K in Q2 2016.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.